Genmab — Maj 2020
-
-
Bulder, kan ikke linke p.t. Men se på Q1 regnskab, afsnittet "Partner-owned Products Incorporating Genmab’s Innovation"
-
Hvis du ikke kan finde det, så kan jeg linke i aften
-
Også fra Genmab Q1: Amivantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer
targets. Amivantamab was created under a collaboration between Genmab and Janssen using Genmab’s
DuoBody technology. The two antibodies used to generate amivantamab were both created by Genmab.
Janssen is investigating amivantamab in a Phase II clinical study to treat NSCLC. -
kkjoel..Søgefunktionen i chatten har desværre aldrig rigtigt fungeret optimalt.
-
-
-
Enig Bulder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind